COYA THERAPEUTICS INC宣布，其用于治疗肌萎缩侧索硬化症（ALS）的在研药物Coya 302，已获得美国食品药品监督管理局（FDA）授予的快速通道资格认定。
这一认定旨在加速针对严重疾病且存在未满足医疗需求药物的开发和审评进程。对于Coya Therapeutics而言，这标志着其ALS疗法研发项目向前迈出了关键一步，有望为患者带来新的治疗希望。
COYA THERAPEUTICS INC宣布，其用于治疗肌萎缩侧索硬化症（ALS）的在研药物Coya 302，已获得美国食品药品监督管理局（FDA）授予的快速通道资格认定。
这一认定旨在加速针对严重疾病且存在未满足医疗需求药物的开发和审评进程。对于Coya Therapeutics而言，这标志着其ALS疗法研发项目向前迈出了关键一步，有望为患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.